Chemotherapy Immunophenoprofiles in Non–small-cell Lung Cancer by Personalized Membrane Proteomics

English | 正體中文 | 简体中文 | Items with full text/Total items : 45422/58598 (78%)
Visitors : 2551123 Online Users : 291

RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.

Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer

TMUIR > Works submitted for Review > Scholarly output for promotion > 109 > Item 987654321/65450

Please use this identifier to cite or link to this item: http://libir.tmu.edu.tw/handle/987654321/65450

Title:	Chemotherapy Immunophenoprofiles in Non–small-cell Lung Cancer by Personalized Membrane Proteomics
Authors:	韓嘉莉 Denise Utami Putri, Po-Hao Feng, Yuu-Hueih Hsu, Kang-Yun Lee, Feng-Wen Jiang, Lu-Wei Kuo, Yu-Ju Chen, Chia-Li Han
Contributors:	臨床藥物基因體學暨蛋白質體學碩士學位學程
Keywords:	Keywords: non-small-cell lung cancer;peripheral blood mononuclear cells;personalized membrane proteomics
Date:	2018-03
Issue Date:	2025-04-02 14:10:43 (UTC+8)
Abstract:	Abstract Objectives: No study has addressed how the immune status at the molecular level is affected by first-line pemetrexed and cisplatin (PEM-CIS) combination therapy in patients with non-small-cell lung cancer (NSCLC). Thus, we aimed to identify the immune status from membrane proteome alterations in patients with NSCLC upon PEM-CIS treatment. Methods: The paired peripheral blood mononuclear cells (PBMCs) were collected from four patients with lung adenocarcinoma before and after the first regimen of PEM-CIS treatment and applied quantitative membrane proteomics analysis. Result: In the personalized PBMC membrane proteome profiles, 2424 proteins were identified as displaying patient-specific responsive patterns. We discovered an elevated neutrophil activity and a more suppressive T-cell phenotype with the downregulation of cytotoxic T lymphocyte antigen 4 degradation and the upregulation of type 2 T-helper and T-regulatory cells in the patient with the highest progression-free survival (PFS) of 14.5 months. Patients with a PFS of 2 months showed higher expressions of T-cell subsets, MHC class II pathways, and T-cell receptor signaling, which indicated an activated immune status. Conclusion and clinical relevance: Without the additional isolation of specific immune cell populations, our study demonstrated that PEM-CIS chemotherapy altered patients' immune system in terms of neutrophils, T cells, and antigen presentation pathways.
Relation:	Proteomics Clin Appl. 2018 Mar; 12(2)
Description:	【109-2 升等】臺北醫學大學教師升等專門著作職別：專任送審等級：副教授著作送審
Note:	Erratum in Chemotherapy Immunophenoprofiles in Non-Small-Cell Lung Cancer by Personalized Membrane Proteomics. Utami Putri D, Feng PH, Hsu YH, Lee KY, Jiang FW, Kuo LW, Chen YJ, Han CL. Proteomics Clin Appl. 2020 Mar;14(2):e1970064. doi: 10.1002/prca.201970064. Epub 2020 Jan 24.
Data Type:	article
Appears in Collections:	[Scholarly output for promotion] 109

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	4	View/Open

著作權聲明 Copyright Notice

本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。
The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.
瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。
By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.
本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。
TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

Loading...